Role of ILC2s in Solid Tumors: Facilitate or Inhibit?

Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 886045
Main Authors Wu, Lige, Zhao, Weiqing, Tang, Shuxian, Chen, Rui, Ji, Mei, Yang, Xin
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 03.06.2022
Subjects
cytokine
group 2 innate lymphoid cell
immunity
Immunology
inflammation
tumor
Online AccessGet full text

Cover

More Information
Summary:Group 2 innate lymphoid cells (ILC2s) are important mediators of type 2 immunity and play an important role in allergic diseases, helminth infections, and tissue fibrosis. However, the role of ILC2s in tumor immunity requires further elucidation. Studies over the past decade have reported that ILC2s play a promoting or suppressing role in different tumors. Here we reviewed the role of ILC2s in solid tumors demonstrating that ILC2s act as a crucial regulator in tumor immunity. We proposed that ILC2s could be an important predictor for tumor prognosis and a new therapeutic target after immunotherapy resistance. In conclusion, our study shed new light on modifying and targeting ILC2s for anti-tumor immunotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Dagmar Stoiber, Karl Landsteiner University of Health Sciences, Austria
Reviewed by: Paula Licona-Limón, National Autonomous University of Mexico, Mexico; Jan-Hendrik Schroeder, King’s College London, United Kingdom
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.886045